Compare Ascendis Pharma A/S (ASND) vs US Bancorp (USB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs US Bancorp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while US Bancorp trades at $62.41 (market cap $97.22B). The key difference: US Bancorp is far larger — about 5.5× Ascendis Pharma A/S's market cap, and US Bancorp pays a 3.33% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | USB | |
|---|---|---|
Market Cap | $17.74B | $97.22B |
Sector | Health | Financials |
52-Week High | $277.18 | $62.89 |
52-Week Low | $163.32 | $43.94 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
U.S. Bancorp (USB) trades at $62.41, up 0.82% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with three consecutive quarterly earnings beats, a P/E of 13.08, and net income margin of 27.04%. Recent developments include the launch of Enhanced Payments for small businesses and a planned dividend increase following successful stress test results.
The outlook remains positive with analyst consensus targeting $67.00 (7.4% upside). Key opportunities include sustained earnings growth and dividend reliability, while risks involve negative cash flow trends and rising debt-to-asset ratios. The stock presents a balanced risk-reward profile for value-oriented investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
